Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 32,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo/Control Clear all
Completed Phase 2 Interventional

A Study With RO4917523 in Patients With Fragile X Syndrome

NCT01015430
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Placebo (for RO4917523 ascending doses), Placebo (for RO4917523 fixed dose), RO4917523
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Sacramento, California • Decatur, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Replacement Study

NCT00957528
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Results available

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
View directory record Official record
Conditions
COPD
Interventions
indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 21, 2026, 12:45 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Not listed Phase 2 Interventional

Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy

NCT02802267
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Inecalcitol, Placebo Oral Tablet
Drug
Lead sponsor
Hybrigenics Corporation
Industry
Eligibility
65 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Varenicline to Reduce Alcohol Consumption in Heavy Drinkers

NCT00695500
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Vijay Ramchandani, Ph.D.
NIH
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00104507
View directory record Official record
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

NCT01500200
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 21, 2026, 12:45 AM EDT
Not listed Phase 2 Interventional

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

NCT04242407
View directory record Official record
Conditions
Pain, Postoperative
Interventions
DMTS, Placebo
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Effect of PF-00734200 in Subjects With Type 2 Diabetes

NCT00618007
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

NCT00448292
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
PRX-00023, Placebo for PRX-00023
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
21
States / cities
Mesa, Arizona • Encino, California • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2007 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Mixed Working Memory Training on Subsequent Training Gains Among Older Adults

NCT05672771
View directory record Official record
Conditions
Cognitive Aging
Interventions
Different Mixed Condition (DM), Different Single Condition (DS), Same Task (ST) Practice Control, Non-WM Placebo Control (PC)
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
60 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 21, 2026, 12:45 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shatavari Root Extract for Perimenopausal Symptoms

NCT07441109
View directory record Official record
Conditions
Perimenopause, Women Health
Interventions
Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
40 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109
View directory record Official record
Conditions
Metabolic Diseases
Interventions
Oral Glucose Tolerance Test, Kisspeptin, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Recruiting Phase 3 Interventional

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 35 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Terminated Phase 1 Interventional

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

NCT00418132
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study of EXT608 in Healthy Adults

NCT05408663
View directory record Official record
Conditions
Safety Issues
Interventions
EXT608, Placebo
Drug · Other
Lead sponsor
Extend Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Not applicable Interventional

Influencer E-Cigarette and Cannabis Marketing: a Survey-Based Experiment Among Adolescents

NCT06919263
View directory record Official record
Conditions
Electronic Nicotine Delivery Systems
Interventions
Influencer marketing
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
16 Years to 17 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 12:45 AM EDT
Recruiting Phase 2 Interventional

Regeneron AA Multicenter (Dupilumab)

NCT05551793
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Irvine, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
39
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 12:45 AM EDT
Recruiting Phase 3 Interventional

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Phase III Confirmatory Study in Erythropoietic Protoporphyria

NCT01605136
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
Afamelanotide, Placebo
Drug
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

NCT05293171
View directory record Official record
Conditions
Healthy Subjects
Interventions
1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 21, 2026, 12:45 AM EDT